Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Combination Therapy in Drug-naïve Korean Type 2 Diabetic Patients
NCT02188186Phase 4Completed
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jul 2014
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sitagliptin and lobeglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Change of Hemoglobin A1c at 12 months. Started Jul 2014; status: completed.
02
Drugs
sitagliptinlobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02188186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02188186.